HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Complete remission of recurrent and refractory uterine epithelioid leiomyosarcoma using weekly administration of bevacizumab and temozolomide.

AuthorsMasashi Takano, Yoshihiro Kikuchi, Nobuyuki Susumu, Kazuya Kudoh, Tsunekazu Kita, Hiroko Kouta, Tomoko Goto, Kenichi Furuya
JournalEuropean journal of obstetrics, gynecology, and reproductive biology (Eur J Obstet Gynecol Reprod Biol) Vol. 157 Issue 2 Pg. 236-8 (Aug 2011) ISSN: 1872-7654 [Electronic] Ireland
PMID21440979 (Publication Type: Case Reports, Letter)
Chemical References
  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents, Alkylating
  • Bevacizumab
  • Dacarbazine
  • Temozolomide
Topics
  • Adult
  • Angiogenesis Inhibitors (therapeutic use)
  • Antibodies, Monoclonal, Humanized (therapeutic use)
  • Antineoplastic Agents, Alkylating (therapeutic use)
  • Bevacizumab
  • Dacarbazine (analogs & derivatives, therapeutic use)
  • Dose-Response Relationship, Drug
  • Drug Therapy, Combination
  • Female
  • Humans
  • Leiomyosarcoma (drug therapy, prevention & control)
  • Neoplasm Recurrence, Local (drug therapy, prevention & control)
  • Remission Induction (methods)
  • Temozolomide
  • Uterine Neoplasms (drug therapy, prevention & control)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: